MYC RNAi-PT Combination Nanotherapy for Metastatic Prostate Cancer Treatment
Abstract
MYC is an oncogene that is often aberrantly overexpressed in many cancers and has been implicated in prostate cancer development and progression to platinum drug resistance. Therefore, it is expected that effective synergistic effect could be achieved by targeting MYC and combining platinum therapy in metastatic prostate cancer treatment. Nevertheless, MYC has traditionally been considered "undruggable" and no effective inhibitors have been identified against this excellent therapeutic target. Led by a team of investigators from Brigham and Women s Hospital/Harvard Medical School, Johns Hopkins University School of Medicine, and University of Maryland Baltimore County, this project aims to develop innovative nanoparticles for the treatment of metastatic prostate cancer. These self-assembled nanoparticles will be designed to carry both MYC siRNA (small interfering RNA that can silence the expression and activity of MYC) and platinum drug. This team has also developed a first-in-field, genetically engineered mouse model of metastatic prostate cancer that expresses MYC, with which the nanoparticle-based combination therapy method can be validated. The successful completion of this project will generate a nanoparticle candidate ready for preclinical and clinical development in treating patients with metastatic prostate cancer. Furthermore, this project will advance the field of prostate cancer research by addressing the critical role of MYC in cancer development/metastasis and platinum drug resistance.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Apr 04, 2016
- Source ID
- W81XWH1510728
Entities
People
- Omid C. Farokhzad
Organizations
- United States Army